TWD
NRIX icon

True Wealth Design’s Nurix Therapeutics NRIX Stock Holding History

True Wealth Design’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$874 Buy
+36
New +$613 ﹤0.01% 2037
2025
Q2 		– Sell
-4
Closed -$48 – 2743
2025
Q1 		$48 Buy
+4
New +$67 ﹤0.01% 2394
2024
Q4 		– Sell
-15
Closed -$338 – 1470
2024
Q3 		$338 Buy
+15
New +$340 ﹤0.01% 1145

Other funds holding NRIX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

True Wealth Design's NRIX Position: Q2 2026 in Review

True Wealth Design opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 36 shares worth $874. The stake represents ﹤0.01% of the portfolio and ranks #2037 among its holdings. This is a return to the name: True Wealth Design previously reported a position in NRIX as recently as Q1 2025.

True Wealth Design first reported a position in NRIX in Q3 2024 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • True Wealth Design held 36 shares of Nurix Therapeutics worth $874 as of Q2 2026.
  • Nurix Therapeutics was a new True Wealth Design position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2037 holding.
  • True Wealth Design first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.